Revolution Medicines (RVMD) Income towards Parent Company (2019 - 2025)
Historic Income towards Parent Company for Revolution Medicines (RVMD) over the last 7 years, with Q3 2025 value amounting to -$305.2 million.
- Revolution Medicines' Income towards Parent Company fell 9528.43% to -$305.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$960.9 million, marking a year-over-year decrease of 6945.81%. This contributed to the annual value of -$600.0 million for FY2024, which is 3750.95% down from last year.
- As of Q3 2025, Revolution Medicines' Income towards Parent Company stood at -$305.2 million, which was down 9528.43% from -$247.8 million recorded in Q2 2025.
- Revolution Medicines' 5-year Income towards Parent Company high stood at -$37.2 million for Q1 2021, and its period low was -$305.2 million during Q3 2025.
- In the last 5 years, Revolution Medicines' Income towards Parent Company had a median value of -$98.3 million in 2023 and averaged -$117.8 million.
- As far as peak fluctuations go, Revolution Medicines' Income towards Parent Company plummeted by 727.28% in 2022, and later crashed by 18587.08% in 2023.
- Quarter analysis of 5 years shows Revolution Medicines' Income towards Parent Company stood at -$52.7 million in 2021, then decreased by 7.27% to -$56.5 million in 2022, then tumbled by 185.87% to -$161.5 million in 2023, then fell by 20.42% to -$194.5 million in 2024, then tumbled by 56.9% to -$305.2 million in 2025.
- Its Income towards Parent Company was -$305.2 million in Q3 2025, compared to -$247.8 million in Q2 2025 and -$213.4 million in Q1 2025.